Walleye Capital
SUPN icon

Walleye Capital’s Supernus Pharmaceuticals SUPN Stock Holding History

Walleye Capital’s Portfolio SUPN Stock Details SUPN Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		– Sell
-11,214
Closed -$580K – 5152
2026
Q1 		$580K Sell
11,214
-17,483
-61% -$890K ﹤0.01% 2539
2025
Q4 		$1.43M Buy
+28,697
New +$1.4M ﹤0.01% 2149
2022
Q4 		– Sell
-13,897
Closed -$470K – 3619
2022
Q3 		$470K Buy
13,897
+122
+0.9% +$3.97K 0.01% 1523
2022
Q2 		$398K Sell
13,775
-36,863
-73% -$1.06M 0.01% 1159
2022
Q1 		$1.64M Buy
+50,638
New +$1.55M 0.04% 432

Other funds holding SUPN

BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
Millennium Management
Millennium Management New York $276B AUM 44.8% 1-Year Est. Return
Vanguard Portfolio Management
Vanguard Portfolio Management Malvern, Pennsylvania $2.22T AUM
AC
Armistice Capital New York $8.17B AUM 68.82% 1-Year Est. Return
Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return
NAMI
Nomura Asset Management International Philadelphia, Pennsylvania $66.6B AUM
Dimensional Fund Advisors
Dimensional Fund Advisors Austin, Texas $552B AUM 44.19% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return
SIMG
Stephens Investment Management Group Houston, Texas $9.33B AUM 56.1% 1-Year Est. Return

Walleye Capital's SUPN Position: Q2 2026 in Review

Walleye Capital sold out of Supernus Pharmaceuticals (SUPN) in Q2 2026, closing a stake of 11,214 shares — an estimated $580K sold.

Walleye Capital first reported a position in SUPN in Q1 2022 and held it in 5 quarters. The position peaked at $1.64M in Q1 2022. 334 funds tracked by Wall St. Rank hold SUPN as of Q2 2026.

  • Walleye Capital reported no remaining Supernus Pharmaceuticals position as of Q2 2026 after selling out during the quarter.
  • Walleye Capital sold 11,214 Supernus Pharmaceuticals shares in Q2 2026, an estimated $580K.
  • Walleye Capital first reported a position in Supernus Pharmaceuticals in Q1 2022 and held it in 5 quarters.
  • Walleye Capital's Supernus Pharmaceuticals position peaked at $1.64M in Q1 2022.
  • 334 funds tracked by Wall St. Rank held Supernus Pharmaceuticals as of Q2 2026.

Based on Walleye Capital's 13F filing for Q2 2026, filed 3 Aug 2026.